{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/ESS30008","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00046176","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized","arm_groups":[],"assignment":"Parallel Assignment","brief_summary":"This study is a 48-week study designed to evaluate the safety and efficacy of a fixed-dose combination tablet administered once-a-day versus the individual tablets administered twice-a-day within 3-drug combination regimens in ART (antiretroviral)-experienced HIV-1 infected patients.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus I","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:37:07","criteria":"Inclusion Criteria: - Currently receiving an initial antiretroviral therapy (ART) regimen composed of the drug abacavir (ABC) 300mg twice a day, plus the drug 3TC (lamivudine) 150mg twice a day in combination with either a protease inhibitor or non-nucleoside reductase inhibitor (NNRTI) for at least 24 weeks. - NOTE: Subjects who have required a change in initial protease inhibitor (PI) or NNRTI therapy due to intolerance (not treatment failure) are eligible. Subject must be on a stable regimen of the second PI or NNRTI therapy for at least 6 months before enrollment in this study. - Plasma HIV-1 RNA less than 400 copies/mL for at least 3 months immediately preceding the screening visit, and at screening. - CD4+ cell count of at least 50 cells/mm3 at screening. - Written informed consent to participate in the study before participation. - Male or female (Females of child-bearing potential must have a negative serum pregnancy test at screening and agree to an acceptable method of contraception.) Exclusion Criteria: - History of a CDC Clinical Category C event requiring treatment (not including cutaneous Kaposi's sarcoma) within 45 days of the screening visit. Treatment for the acute event must have been completed at least 30 days before screening. - Subject is enrolled in one or more investigational drug studies which may impact HIV RNA suppression. - Subject is unable to complete the 48-week dosing period, evaluations and assessments. - Subject is pregnant or breastfeeding. - History of clinically relevant inflammation of the pancreas or hepatitis within 6 months prior to screening. - Subject suffers from a serious medical condition, such as diabetes or heart problem. - Pre-existing mental, physical, or substance abuse disorder. - History of inflammatory bowel disease or malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction. - Abnormal laboratory results within 28 days before the first dose of study medication. - Required treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days before screening, or will need these during the study. - Subject requires treatment with immunomodulating drugs such as systemic corticosteroids, interleukins, vaccines, or interferons within 28 days prior to screening, or subject has received an HIV-1 immunotherapeutic vaccine within 90 days prior to screening. - Asthmatic subjects using inhaled corticosteroids are eligible for enrollment. - Subject requires treatment with foscarnet, hydroxyurea or other agents with documented activity against HIV-1 in vitro within 28 days of screening. - Subject has a history of allergy to any of the study drugs.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"240","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"e85f6301-2e56-5b69-ab1b-c7a8ef1686df","internal":{"content":null,"contentDigest":"9821a1c7201c4b9b7eb001493d910cc4","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Currently receiving an initial antiretroviral therapy (ART) regimen composed of the drug abacavir (ABC) 300mg twice a day, plus the drug 3TC (lamivudine) 150mg twice a day in combination with either a protease inhibitor or non-nucleoside reductase inhibitor (NNRTI) for at least 24 weeks. - NOTE: Subjects who have required a change in initial protease inhibitor (PI) or NNRTI therapy due to intolerance (not treatment failure) are eligible. Subject must be on a stable regimen of the second PI or NNRTI therapy for at least 6 months before enrollment in this study. - Plasma HIV-1 RNA less than 400 copies/mL for at least 3 months immediately preceding the screening visit, and at screening. - CD4+ cell count of at least 50 cells/mm3 at screening. - Written informed consent to participate in the study before participation. - Male or female (Females of child-bearing potential must have a negative serum pregnancy test at screening and agree to an acceptable method of contraception.) Exclusion Criteria: - History of a CDC Clinical Category C event requiring treatment (not including cutaneous Kaposi's sarcoma) within 45 days of the screening visit. Treatment for the acute event must have been completed at least 30 days before screening. - Subject is enrolled in one or more investigational drug studies which may impact HIV RNA suppression. - Subject is unable to complete the 48-week dosing period, evaluations and assessments. - Subject is pregnant or breastfeeding. - History of clinically relevant inflammation of the pancreas or hepatitis within 6 months prior to screening. - Subject suffers from a serious medical condition, such as diabetes or heart problem. - Pre-existing mental, physical, or substance abuse disorder. - History of inflammatory bowel disease or malignancy, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction. - Abnormal laboratory results within 28 days before the first dose of study medication. - Required treatment with radiation therapy or cytotoxic chemotherapeutic agents within 28 days before screening, or will need these during the study. - Subject requires treatment with immunomodulating drugs such as systemic corticosteroids, interleukins, vaccines, or interferons within 28 days prior to screening, or subject has received an HIV-1 immunotherapeutic vaccine within 90 days prior to screening. - Asthmatic subjects using inhaled corticosteroids are eligible for enrollment. - Subject requires treatment with foscarnet, hydroxyurea or other agents with documented activity against HIV-1 in vitro within 28 days of screening. - Subject has a history of allergy to any of the study drugs.","interventions":[{"arm_group_label":"","intervention_description":"","intervention_name":"abacavir/lamivudine","intervention_type":"Drug"},{"arm_group_label":"","intervention_description":"","intervention_name":"abacavir","intervention_type":"Drug"},{"arm_group_label":"","intervention_description":"","intervention_name":"lamivudine","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":null,"is_high_value":false,"is_ind_study":true,"keywords":["HIV-1 Abacavir Lamivudine Antiretroviral-experienced"],"last_follow_up_date":null,"links":[],"locations":[{"City":"Fort Lauderdale","Latitude":"26.1897731","CountryDisplay":"United States","Longitude":"-80.1037721","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33308","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Augusta","Latitude":"33.4706725","CountryDisplay":"United States","Longitude":"-81.9861463","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30912","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Washington","Latitude":"38.9156487","CountryDisplay":"United States","Longitude":"-77.0737149","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20007","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Baltimore","Latitude":"39.2963369","CountryDisplay":"United States","Longitude":"-76.6210539","Name":"GSK Investigational Site","StateDisplay":"Maryland","PostalCode":"21201","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Durham","Latitude":"36.0038131","CountryDisplay":"United States","Longitude":"-78.9387241","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27710","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"27.9552692","CountryDisplay":"United States","Longitude":"-82.4563199","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33602","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"26.0977657","CountryDisplay":"United States","Longitude":"-80.1261093","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33316","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Charlotte","Latitude":"35.1811188","CountryDisplay":"United States","Longitude":"-80.8488498","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"28209","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Baltimore","Latitude":"39.2963369","CountryDisplay":"United States","Longitude":"-76.6210539","Name":"GSK Investigational Site","StateDisplay":"Maryland","PostalCode":"21201","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7457134","CountryDisplay":"United States","Longitude":"-96.8458204","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75208","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ponce","Latitude":"18.1311468","CountryDisplay":"Puerto Rico","Longitude":"-66.6395219","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"00731","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Torrance","Latitude":"33.8331717","CountryDisplay":"United States","Longitude":"-118.2906661","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90502","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7686973","CountryDisplay":"United States","Longitude":"-73.9918181","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10019","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Orlando","Latitude":"28.5085825","CountryDisplay":"United States","Longitude":"-81.3564411","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32806","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Francisco","Latitude":"37.7877522","CountryDisplay":"United States","Longitude":"-122.4382307","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94115-1931","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Panama City","Latitude":"8.9823792","CountryDisplay":"Panama","Longitude":"-79.5198696","Name":"GSK Investigational Site","StateDisplay":"Panamá","PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.1012181","CountryDisplay":"United States","Longitude":"-118.325739","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90028","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Wichita","Latitude":"37.7040524","CountryDisplay":"United States","Longitude":"-97.3138554","Name":"GSK Investigational Site","StateDisplay":"Kansas","PostalCode":"67214","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Rio Piedras","Latitude":"18.403745","CountryDisplay":"Puerto Rico","Longitude":"-66.0537881","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"925","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hampton","Latitude":"37.0538822","CountryDisplay":"United States","Longitude":"-76.3984537","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"23666","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Washington","Latitude":"38.9191485","CountryDisplay":"United States","Longitude":"-77.0362967","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20009","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Knoxville","Latitude":"35.9536716","CountryDisplay":"United States","Longitude":"-83.9281092","Name":"GSK Investigational Site","StateDisplay":"Tennessee","PostalCode":"37916","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"San Jose","Latitude":"9.9280694","CountryDisplay":"Costa Rica","Longitude":"-84.0907246","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":null,"StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Stony Brook","Latitude":"40.9132244","CountryDisplay":"United States","Longitude":"-73.1261091","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"11794","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hillsborough","Latitude":"40.5106594","CountryDisplay":"United States","Longitude":"-74.6472522","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"08844","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tampa","Latitude":"28.0133862","CountryDisplay":"United States","Longitude":"-82.5077593","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33614","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Columbia","Latitude":"34.0258687","CountryDisplay":"United States","Longitude":"-80.9594751","Name":"GSK Investigational Site","StateDisplay":"South Carolina","PostalCode":"29206-4713","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami","Latitude":"25.7307897","CountryDisplay":"United States","Longitude":"-80.2377078","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33133","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7464969","CountryDisplay":"United States","Longitude":"-74.0094471","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10011","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Jacksonville","Latitude":"30.346791","CountryDisplay":"United States","Longitude":"-81.6418656","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32206","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Tulsa","Latitude":"36.1870511","CountryDisplay":"United States","Longitude":"-96.0361574","Name":"GSK Investigational Site","StateDisplay":"Oklahoma","PostalCode":"74127","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.8676889","CountryDisplay":"United States","Longitude":"-84.4645184","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30339","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Denver","Latitude":"39.7316982","CountryDisplay":"United States","Longitude":"-104.9213643","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80220","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Phoenix","Latitude":"33.4636012","CountryDisplay":"United States","Longitude":"-112.0535987","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85006","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Plantation","Latitude":"26.1218038","CountryDisplay":"United States","Longitude":"-80.2209773","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33317","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Myers","Latitude":"26.6235485","CountryDisplay":"United States","Longitude":"-81.8770671","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33901","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.8122051","CountryDisplay":"United States","Longitude":"-96.8109852","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75219","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Greenville","Latitude":"35.5371999","CountryDisplay":"United States","Longitude":"-77.3209555","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27858","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Akron","Latitude":"41.0801473","CountryDisplay":"United States","Longitude":"-81.5020328","Name":"GSK Investigational Site","StateDisplay":"Ohio","PostalCode":"44304","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Hershey","Latitude":"40.2713328","CountryDisplay":"United States","Longitude":"-76.6297189","Name":"GSK Investigational Site","StateDisplay":"Pennsylvania","PostalCode":"17033","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fountain Valley","Latitude":"33.7168761","CountryDisplay":"United States","Longitude":"-117.9600466","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"92708","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Orlando","Latitude":"28.5747416","CountryDisplay":"United States","Longitude":"-81.3949264","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32804","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Somers Point","Latitude":"39.3140235","CountryDisplay":"United States","Longitude":"-74.5990492","Name":"GSK Investigational Site","StateDisplay":"New Jersey","PostalCode":"08244","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Fort Lauderdale","Latitude":"25.750008","CountryDisplay":"United States","Longitude":"-80.241826","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33145","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.7962048","CountryDisplay":"United States","Longitude":"-96.7694752","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75246","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"New York","Latitude":"40.7366138","CountryDisplay":"United States","Longitude":"-74.0094471","Name":"GSK Investigational Site","StateDisplay":"New York","PostalCode":"10014","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Decatur","Latitude":"33.8092255","CountryDisplay":"United States","Longitude":"-84.2805478","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30033","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sacramento","Latitude":"38.5890819","CountryDisplay":"United States","Longitude":"-121.4084731","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"95825","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Miami","Latitude":"25.7870967","CountryDisplay":"United States","Longitude":"-80.2042436","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33136","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Houston","Latitude":"29.7209034","CountryDisplay":"United States","Longitude":"-95.3677844","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77004","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.1012181","CountryDisplay":"United States","Longitude":"-118.325739","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90028","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Denver","Latitude":"39.7558119","CountryDisplay":"United States","Longitude":"-104.9680914","Name":"GSK Investigational Site","StateDisplay":"Colorado","PostalCode":"80205","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Dallas","Latitude":"32.799475","CountryDisplay":"United States","Longitude":"-96.7868794","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"75204","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.0502898","CountryDisplay":"United States","Longitude":"-118.2117257","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90033","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Long Beach","Latitude":"33.7844997","CountryDisplay":"United States","Longitude":"-118.1971031","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90813","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Reading","Latitude":"40.3537241","CountryDisplay":"United States","Longitude":"-75.9405178","Name":"GSK Investigational Site","StateDisplay":"Pennsylvania","PostalCode":"19601","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Houston","Latitude":"29.740582","CountryDisplay":"United States","Longitude":"-95.4515725","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77027","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Atlanta","Latitude":"33.7717008","CountryDisplay":"United States","Longitude":"-84.3726049","Name":"GSK Investigational Site","StateDisplay":"Georgia","PostalCode":"30308","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 23:05:31","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Phase III, 48-Week, Open-Label, Randomized, Multicenter Study of the Safety and Efficacy of the Abacavir/Lamivudine Fixed-Dose Combination Tablet Administered QD Versus Abacavir + Lamivudine Administered BID in Combination with a PI or NNRTI in Antiretroviral Experienced Patients.","org_study_id":"ESS30008","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"3","primary_compl_date":null,"primary_outcomes":[{"outcome_description":"","outcome_measure":"Proportion of non-virologic failures through Week 48. Treatment-limiting adverse events over 48 weeks.","outcome_time_frame":"48 weeks","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Viral load response at Week 24 and 48 T-cell count Disease progression Health outcomes Resistance","outcome_time_frame":"48 weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"None","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"08/01/2002 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[{"citation":"ABACAVIR + LAMIVUDINE FIXED DOSE COMBINATION TABLET ONCE DAILY (QD) COMPARED WITH ABACAVIR (ABC) AND LAMIVUDINE (3TC) TWICE DAILY (BID) IN HIV-1 INFECTED SUBJECTS (ESS30008). Hill-Zabala, Christina E. PharmD 1, Sosa, Nestor MD 2, DeJesus, Edwin MD 3, Herrera, Gisella MD, Florance, Allison M. MS , Watson, Maria E. PhD , and Shaefer, Mark S. PharmD (144F), 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA; USA, 10/23/2005","is_results_ref":"Yes","pubmed_id":""},{"citation":"EFFICACY AND SAFETY OF A ONCE DAILY FIXED-DOSE COMBINATION OF ABACAVIR/LAMIVUDINE (ABC/3TC) [FDC ] VERSUS ABC TWICE DAILY AND 3TC ONCE DAILY AS SEPARATE ENTITIES [SE] IN ART-EXPERIENCED HIV-1 INFECTED SUBJECTS (CAL30001): 48 WEEK DATA. Clumeck, N., LaMarca, A., Fu, K., Gordon, D., Craig, C., Zhao, H., Paes, D., and Scott, T. (WePe6.3C13), 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro; Brazil, 7/24/2005","is_results_ref":"Yes","pubmed_id":""},{"citation":"Sosa N, DeJesus E, Hill-Zabala C, et al. Abacavir + lamivudine (ABC/3TC) fixed-dose combination tablet once-daily compared with abacavir and lamivudine twice-daily in HIV-1-infected subjects over 48 weeks (ESS30008). 2th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005. [poster 572]","is_results_ref":"Yes","pubmed_id":""},{"citation":"PATIENT SATISFACTION WITH ABACAVIR (ABC)-LAMIVUDINE (3TC) FIXED DOSE COMBINATION (FDC) TABLET ONCE DAILY (QD) COMPARED WITH ABC AND 3TC TWICE DAILY (BID) IN HIV-1 INFECTED PATIENTS (ESS30008). Hill-Zabala, Christina E. PharmD , Watson, Maria E. PhD , Sosa, Nestor MD , DeJesus, Edwin MD , and Florance, Allison M. MS (145E), 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA; USA, 10/23/2005","is_results_ref":"Yes","pubmed_id":""},{"citation":"ABACAVIR AND LAMIVUDINE FIXED-DOSE COMBINATION TABLET ONCE DAILY COMPARED WITH ABACAVIR AND LAMIVUDINE TWICE DAILY IN HIV-INFECTED PATIENTS OVER 48 WEEKS (ESS30008, SEAL). Sosa, N., Hill-Zabala, C., Dejesus, E., Herrera, G., Florance, A., Watson, M., Vavro, C., and Shaefer, M. J Acquir Immune Defic Syndr. 2005 Dec 1; 40(4):422-427","is_results_ref":"Yes","pubmed_id":""},{"citation":"Sosa N, DeJesus E, Hill-Zabala C, et al. Abacavir + lamivudine (ABC/3TC) fixed-dose combination tablet once-daily compared with abacavir and lamivudine twice-daily in HIV-1-infected subjects (ESS30008). 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 14-18, 2004 . [poster P45]","is_results_ref":"Yes","pubmed_id":""}],"is_section_801":null}},"pageContext":{"studyId":"ESS30008"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}